Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Nervenarzt ; 88(3): 215-221, 2017 Mar.
Artículo en Alemán | MEDLINE | ID: mdl-27251738

RESUMEN

Sleep plays an essential role in memory consolidation. Although sleep problems are common in Alzheimer's disease, they are not usually thought to be key features of the disease; however, new experimental research has shown that sleep disturbances not only occur before the onset of typical cognitive deficits but are also associated with the pathogenesis of Alzheimer's disease and may have a decisive influence on the symptoms and course. Thus, sleep disturbances may be potentially modifiable risk factors for Alzheimer's disease that deserve more attention in research, diagnostics and treatment.


Asunto(s)
Enfermedad de Alzheimer/fisiopatología , Amnesia/fisiopatología , Encéfalo/fisiopatología , Placa Amiloide/fisiopatología , Trastornos del Inicio y del Mantenimiento del Sueño/fisiopatología , Sueño , Enfermedad de Alzheimer/complicaciones , Medicina Basada en la Evidencia , Humanos , Modelos Neurológicos , Placa Amiloide/complicaciones , Trastornos del Inicio y del Mantenimiento del Sueño/complicaciones
2.
Nervenarzt ; 87(11): 1163-1174, 2016 Nov.
Artículo en Alemán | MEDLINE | ID: mdl-26781314

RESUMEN

Alzheimer's disease (AD) is characterized by the pathological accumulation of amyloid-beta (Abeta) and tau peptides in the brain. Recent evidence suggests that the soluble peptide amyloid-eta (Aeta) may have an additional role in the pathogenesis of AD. The detailed investigation of the cellular and neurophysiological mechanisms underlying AD has revealed surprising results that may become highly relevant for the early diagnosis and treatment of the disease. By analyzing the function of single neurons and large-scale networks in intact brains in vivo it has been shown that A-beta, tau and A-eta abnormally modulate brain activity and obviously unfold contrasting effects: while A-beta promotes neuronal hyperactivity as well as epileptiform activity, tau and A-eta reduce the activity of neurons. Promising new evidence from animal studies and humans with AD indicates that the treatment of hyperactivity may improve cognitive dysfunctions and even slow the underlying disease process.


Asunto(s)
Enfermedad de Alzheimer/fisiopatología , Enfermedad de Alzheimer/terapia , Encéfalo/fisiopatología , Agitación Psicomotora/fisiopatología , Agitación Psicomotora/terapia , Enfermedad de Alzheimer/complicaciones , Medicina Basada en la Evidencia , Humanos , Agitación Psicomotora/complicaciones , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA